ライフサイエンスコーパス: Takayasu

1 Takayasu arteritis is an inflammatory disease of large-d

2 Takayasu arteritis occurs mainly in young women and, if

3 Takayasu's arteritis (TAK) is a large-vessel vasculitis

4 e itself may be accompanied by aortitis or a Takayasu's-like or medium-sized vessel vasculitis.

5 ammatory disorders (giant cell arteritis and Takayasu arteritis) are the most common form of systemic

6 es of patients with giant cell arteritis and Takayasu arteritis, and serum levels of this cytokine mi

7 des, including both giant cell arteritis and Takayasu arteritis, and the aortitis of Cogan syndrome a

8 r's granulomatosis, giant cell arteritis and Takayasu's arteritis in the US amounted to $150 million

9 sts: pentraxin-3 in giant cell arteritis and Takayasu's arteritis; von Willebrand factor antigen in c

10 Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are major forms of large-vess

11 Large vessel vasculitides, such as Takayasu arteritis and giant cell arteritis, affect vita

12 rtery inflammatory vascular disease, such as Takayasu arteritis, chemotherapy- or radiation-induced v

13 history of some of these conditions, such as Takayasu arteritis, includes a very long period of low l

14 ar wall and lumen pathologies resulting from Takayasu arteritis.

15 irin in the prevention of ischemic events in Takayasu's disease.

16 logically similar to the lesions observed in Takayasu's arteritis, the nongranulomatous variant of te

17 The outlook in Takayasu arteritis has improved over the last decade, re

18 ol for disease assessment include the Indian Takayasu Clinical Activity Score (ITAS2010), which incor

19 ed stenoses of its main branches, indicating Takayasu arteritis.

20 ies may help accurately diagnose and monitor Takayasu arteritis (TAK).

21 cause of the wide variation in the course of Takayasu arteritis (TA), predicting outcome is challengi

22 omatous inflammation is a typical feature of Takayasu arteritis (TA), and tumor necrosis factor (TNF)

23 s considered the gold standard in imaging of Takayasu arteritis.

24 ticularly attractive for arterial lesions of Takayasu arteritis.

25 iew recent advances in medical management of Takayasu arteritis, with a special focus on the rational

26 rgery remains important in the management of Takayasu arteritis.

27 boratory, and radiographic manifestations of Takayasu arteritis (TA) in a cohort from the US, evaluat

28 mproved disease activity in small numbers of Takayasu's patients, including those refractory to anti-

29 t they may be effective for the treatment of Takayasu's arteritis, but their role in the treatment of

30 agents are recommended for the treatment of Takayasu's patients who are unable to taper prednisone d

31 rituximab, and some patients with refractory Takayasu arteritis have responded to the immunomodulator

32 pus erythematosus (SLE), systemic sclerosis, Takayasu arteritis, Wegener granulomatosis, Behcet syndr

33 sculopathies, ranging from the vasculitides (Takayasu arteritis, giant cell arteritis, and polyarteri

34 l 9 patients (2 with Marfan syndrome, 1 with Takayasu's disease) with undiagnosed aortic dissection h

35 acteristics and outcomes of 49 patients with Takayasu arteritis (80% female; median age, 42 years [20

36 and outcomes of 79 consecutive patients with Takayasu arteritis (median age, 39 years; interquartile

37 nce (CMR) in the assessment of patients with Takayasu arteritis (TA).

38 ty in approximately 50% of all patients with Takayasu arteritis (TA).

39 A small number of patients with Takayasu arteritis and IgG4-related aortitis have also b

40 rform successful monitoring of patients with Takayasu arteritis and to plan possible interventional t

41 Eighty-eight percent of patients with Takayasu arteritis were inadequately controlled with or

42 geted treatments in refractory patients with Takayasu arteritis with an acceptable safety profile.

43 ons after revascularization in patients with Takayasu arteritis.

44 ntagonists and tocilizumab) in patients with Takayasu arteritis.